Seminars in Nephrology
Volume 26, Issue 6 , Pages 422-433 , November 2006

Inherited Renal Tubulopathies Associated With Metabolic Alkalosis: Effects on Blood Pressure

  • Gema Ariceta

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Dr. Gema Ariceta, Section Chief, Pediatric Nephrology, Hospital Cruces, P/Cruces s/n, 48903 Barakaldo, Vizcaya, Spain.
    • ,
  • Juan Rodríguez-Soriano

References 

  1. Koeppen BM, Stanton BA. Renal Physiology. (ed 3). Philadelphia, PA: Mosby, Inc; 2001;
  2. Rodriguez Soriano J. Tubular disorders of electrolyte regulation. In:  Avner ED,  Harmon WE,  Niaudet P editor. Pediatric Nephrology. (ed 5). Baltimore, MD: Lippincott, William & Wilkins; 2004;p. 729–756
  3. Greger R. Ion transport mechanisms in thick ascending limb of Henle’s loop of mammalian nephron. Physiol Rev. 1985;65:760–797
  4. Hebert SC. An ATP-regulated, inwardly rectifying potassium channel from rat kidney (ROMK). Kidney Int. 1995;48:1010–1016
  5. Ellison DH. Divalent cation transport by the distal nephron: Insights from Bartter’s and Gitelman’s syndromes. Am J Physiol. 2000;279:F616–F625
  6. Biner HL, Arpin-Bott MP, Loffing J, et al. Human cortical distal nephron: Distribution of electrolyte and water transport pathways. J Am Soc Nephrol. 2002;13:836–847
  7. Waldegger S, Jentsch TJ. Functional and structural analysis of ClC-K chloride channels involved in renal disease. J Biol Chem. 2000;275:24527–24533
  8. Estevez R, Boettger T, Stein V, et al. Barttin is a Cl-channel beta-subunit crucial for renal Cl-reabsorption and inner ear K+ secretion. Nature. 2001;414:558–561
  9. Naray-Fejes-Toth A, Canessa C, Cleaveland ES, et al. Sgk is an aldosterone-induced kinase in the renal collecting duct (Effects on epithelial Na+ channels). J Biol Chem. 1999;274:16973–16978
  10. Naray-Fejes-Toth A, Fejes-Toth G. 11 beta-hydroxysteroid dehydrogenase in renal collecting duct cells. Steroids. 1994;59:105–110
  11. Lang F, Capasso G, Schwab M, et al. Renal transport and the genetic basis of hypertensive disease. Clin Exp Nephrol. 2005;9:91–99
  12. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104:545–556
  13. Rodríguez Soriano J. Bartter and related syndromes: The puzzle is almost solved. Pediatr Nephrol. 1998;12:315–327
  14. Rodríguez Soriano J. Potassium homeostasis and its disturbances in children. Pediatr Nephrol. 1995;9:364–374
  15. Sojo A, Rodríguez Soriano J, Vitoria JC, et al. Chloride deficiency as a presentation or complication of cystic fibrosis. Eur J Pediatr. 1994;153:825–828
  16. Hebert SC. Bartter síndrome. Curr Opin Nephrol Hypertens. 2003;12:527–532
  17. Bartter FC, Pronove P, Gill JR, et al. Hyperplasia of juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. Am J Med. 1962;33:811–818
  18. Proesmans W. Bartter syndrome and its neonatal variant. Eur J Pediatr. 1997;156:669–679
  19. Seyberth HW, Rascher W, Schweer W, et al. Congenital hypokalemia with hypercalciuria in preterm infants: A hyperprostaglandinuric tubular syndrome different from Bartter syndrome. J Pediatr. 1985;107:694–701
  20. Simon DB, Karet FE, Hamdan JM, et al. Bartter’s syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet. 1996;13:183–188
  21. Vargas-Poussou R, Feldmann D, Vollmer M, et al. Novel molecular variants of the Na-K-2Cl cotransporter gene are responsible for antenatal Bartter syndrome. Am J Hum Genet. 1998;62:1332–1340
  22. Bettinelli A, Ciarmatori S, Cesareo L, et al. Phenotypic variability in Bartter syndrome type I. Pediatr Nephrol. 2000;14:940–945
  23. International Collaborative Study Group for Bartter-like Syndromes. Mutations in the gene encoding the inwardly-rectifying renal potassium channel, ROMK, cause the antenatal variant of Bartter syndrome: Evidence for genetic heterogeneity. Hum Mol Genet. 1997;6:17–26
  24. Vollmer M, Koehrer M, Topaloglu R, et al. Two novel mutations in the gene for Kir 1.1 (ROMK) in neonatal Bartter syndrome. Pediatric Nephrol. 1997;12:69–71
  25. Jeck N, Derst C, Wischmeyer E, et al. Functional heterogeneity of ROMK mutations linked to hyperprostaglandin E syndrome. Kidney Int. 2001;69:1803–1811
  26. Starremans PGJF, Ersten FFJ, Knoers NVAM, et al. Mutations in the human Na-K-2Cl cotransporter (NKCC2) identified in Bartter syndrome type I consistently result in nonfunctional transporters. J Am Soc Nephrol. 2003;14:1419–1426
  27. Simon DB, Karet FE, Rodríguez-Soriano J, et al. Genetic heterogeneity of Bartter’s syndrome revealed by mutations in the K+ channel, ROMK. Nat Genet. 1996;14:152–156
  28. Starremans PGJ, van der Kemp AWCM, Knoers NVAM, et al. Functional implications of mutations in the human renal outer medullary potassium channel (ROMK2) identified in Bartter syndrome. Pflugers Arch. 2002;443:466–472
  29. Schulte U, Hahn H, Konrad M, et al. pH gating of ROMK (Kir 1.1) channels: Control by an arg-lys-arg triad disrupted in antenatal Bartter syndrome. Proc Natl Acad Sci U S A. 1999;96:15298–15303
  30. Feldman D, Alessandri J-L, Deschênes G. Large deletion of the 5′ end of the ROMK1 gene causes antenatal Bartter syndrome. J Am Soc Nephrol. 1998;9:2357–2359
  31. Peters M, Ermert S, Jeck N, et al. Classification and rescue of ROMK mutations underlying hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int. 2003;64:923–932
  32. Vollmer M, Jeck N, Lemmink HH, et al. Antenatal Bartter syndrome with sensorineural deafness: Refinement of the locus on chromosome 1p31. Nephrol Dial Transplant. 2000;15:970–974
  33. Birkenhäger R, Otto E, Schürman M, et al. Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet. 2001;29:310–314
  34. Hayama A, Rai T, Sasaki S, et al. Molecular mechanisms of Bartter syndrome caused by mutations in the BSND gene. Histochem Cell Biol. 2003;119:485–493
  35. Konrad M, Vollmer M, Lemmink HH, et al. Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome. J Am Soc Nephrol. 2000;11:1449–1459
  36. Schlingmann KP, Konrad M, Jeck K, et al. Salt wasting and deafness resulting from mutations in two chloride channels. N Engl J Med. 2004;350:1314–1319
  37. Matsumura Y, Uchida S, Kondo Y, et al. Overt nephrogenic diabetes insipidus in mice lacking the CLC-K1 chloride channel. Nat Genet. 1999;21:95–98
  38. Derst C, Konrad M, Köckerling L, et al. Mutations in the ROMK gene in antenatal Bartter syndrome are associated with impaired K+ channel function. Biochem Biophys Res Commun. 1997;230:641–645
  39. Macica CM, Yang Y, Hebert SC, et al. Arachidonic acid inhibits activity of cloned renal K+ channel, ROMK1. Am J Physiol. 1996;271:F588–F594
  40. Köckerling A, Reinalter SC, Seyberth HW. Impaired response to furosemide in hyperprostaglandin E syndrome: Evidence for a tubular defect in the loop of Henle. J Pediatr. 1996;129:519–528
  41. Nussing RM, Treude A, Weissenberger C. Dominant role of prostaglandin E2 EP4 receptor in furosemide-induced salt-losing tubulopathy: A model for hyperprostaglandin E syndrome/antenatal Bartter syndrome. J Am Soc Nephrol. 2005;16:2354–2362
  42. Rodríguez Soriano J, Vallo A, Aguirre M. Bone mineral density and bone turnover in patients with Bartter syndrome. Pediatr Nephrol. 2005;20:1120–1125
  43. Proesmans W, Massa G, Vanderberghe K, et al. Prenatal diagnosis in Bartter syndrome. Lancet. 1987;1:394
  44. Matsushita Y, Suzuki Y, Oya N, et al. Biochemical examination of the mother’s urine is useful for prenatal diagnosis of Bartter syndrome. Prenat Diagn. 1999;19:671–673
  45. Konrad M, Leonhardt A, Hensen P, et al. Prenatal and postnatal management of hyperprostaglandin E2 syndrome after genetic diagnosis from amniocytes. Pediatrics. 1999;103:678–683
  46. Filer G, Shalev H, Bilk OS, et al. Transient neonatal hyperkalemia in the antenatal (ROMK defective) Bartter syndrome. J Pediatr. 2003;142:318–323
  47. Rodriguez Soriano J, Vallo A, Garcia-Fuentes M. Hypomagnesemia of hereditary renal origin. Pediatr Nephrol. 1987;1:465–472
  48. Langhendries JP, Thiry V, Bodart E, et al. Exogenous prostaglandin administration and pseudo-Bartter syndrome. Eur J Pediatr. 1989;149:208–209
  49. Rodríguez Soriano J. Bartter’s syndrome comes of age. Pediatrics. 1999;13:663–664
  50. Jeck N, Reinalter BC, Henne T, et al. Hypokalemic salt-losing tubulopathy with chronic renal failure and sensorineural deafness. Pediatrics. 2001;108:E5
  51. Shalev H, Ohali M, Kachko L, et al. The neonatal variant of Bartter syndrome and deafness: Preservation of renal function. Pediatrics. 2003;112:628–633
  52. Komhoff M, Jeck ND, Seyberth HW, et al. Cyclooxygenase 2 expression is associated with the renal macula densa of patients with Bartter-like syndrome. Kidney Int. 2000;58:2420–2424
  53. Nusing RM, Reinalter SC, Peterts M, et al. Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: Therapeutic use of cyclooxygenase-2 inhibitor nimesulide. Clin Pharmacol Ther. 2001;70:384–390
  54. Reinalter SC, Jeck N, Brochhausen C, et al. Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int. 2002;62:253–260
  55. Bettinelli A, Bianchetti MG, Girardin E, et al. Use of calcium excretion values to distinguish two forms of primary renal tubular hypokalemic alkalosis: Bartter and Gitelman syndromes. J Pediatr. 1992;120:38–43
  56. Caló L, Davis PA, Milani M, et al. Bartter’s syndrome and Gitelman’s syndrome: Two entities sharing the same abnormality in vascular reactivity. Clin Nephrol. 1998;50:65–67
  57. Caló L, Davis PA, Milani M, et al. Increased endothelial nitric oxide synthase mRNA level in Bartter’s and Gitelman’s syndrome (Relationship to vascular reactivity). Clin Nephrol. 1999;51:12–17
  58. Calò LA. Vascular tone control in humans: Insights from studies in Bartter’s/Gitelman’s syndromes. Kidney Int. 2006;69:963–966
  59. Simon DB, Bindra RS, Nelson-Williams C, et al. Mutations in the chloride channel ClC-Kb cause Bartter’s syndrome type III. Nat Genet. 1997;17:171–178
  60. Jeck N, Konrad M, Peters M, et al. Mutations in the chloride channel gene, CLCNKB, leading to a mixed Bartter-Gitelman phenotype. Pediatr Res. 2000;48:754–758
  61. Zelikovic I, Szargel R, Hawash A, et al. A novel mutation in the chloride channel gene, CLCNKB, as a cause of Gitelman and Bartter syndromes. Kidney Int. 2003;63:24–32
  62. Rodríguez Soriano J, Vallo A, Pérez de Nanclares G, et al. A founder mutation in the CLCNKB gene causes Bartter syndrome type III in Spain. Pediatr Nephrol. 2005;20:891–896
  63. Bettinelli A, Borsa N, Syrén M-L, et al. Simultaneous mutations in the CLCNKB and SLC12A3 genes in two siblings with phenotypic heterogeneity in classic Bartter syndrome. Pediatr Res. 2005;58:1269–1273
  64. Vargas-Poussou R, Huang C, Hulin P, et al. Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J Am Soc Nephrol. 2002;13:2259–2266
  65. Watanabe S, Fukumoto S, Chang H, et al. Association between activating mutations of calcium-sensing receptor and Bartter’s syndrome. Lancet. 2002;360:692–694
  66. Jeck N, Waldegger S, Lampert A, et al. Activating mutation ofn the renal epithelial chloride channel ClC-Kb predisposing to hypertension. Hypertension. 2004;43:1175–1181
  67. Rodríguez-Soriano J, Vallo A, Castillo G, et al. Renal handling of water and sodium in infancy and childhood: A study using clearance methods during hypotonic saline diuresis. Kidney Int. 1981;20:700–704
  68. Hené RJ, Koomans HA, Dorhout Mees EJ. Suppressed diluting segment reabsorption in Bartter’s syndrome: Studies in 1 patient and synthesis of literature. Am J Nephrol. 1988;8:402–409
  69. Emma F, Pizzini C, Tessa A, et al. “Bartter-like” phenotype in Kearns–Sayre síndrome. Pediatr Nephrol. 2006;21:355–360
  70. Güllner MG, Gill JR, Bartter FC, et al. A familial disorder with hypokalemic alkalosis, hyperreninemia, aldosteronism, high urinary prostaglandins and normal blood pressure that is not “Bartter’s syndrome.”. Trans Assoc Am Physicians. 1979;92:175–178
  71. Güllner HG, Bartter FC, Gill JR, et al. A sibship with hypokalemic alkalosis and renal proximal tubulopathy. Arch Intern Med. 1983;143:1534–1540
  72. Colussi G, Rambolá G, Airaghi C, et al. Pseudo-Bartter’s syndrome from subreptitious diuretic intake: Differential diagnosis with true Bartter’s syndrome. Nephrol Dial Transplant. 1992;7:896–901
  73. D’Avanzo M, Santinelli R, Tolone C, et al. Concealed administration of furosemide simulating Bartter’s syndrome in a 4.5 year-old boy. Pediatr Nephrol. 1995;9:749–750
  74. Arant B, Brackett N, Young R, et al. Case studies of siblings with juxtaglomerular hyperplasia and secondary hyperaldosteronism associated with severe azotemia and renal rickets-Bartter’s syndrome or disease. Pediatrics. 1970;46:344–361
  75. Gitelman HJ, Graham JB, Welt LG. A new familial disorder characterized by hypokaliemia and hypomagnesemia. Trans Assoc Am Physicians. 1966;79:221–223
  76. Ea HK, Blanchard A, Dougados M, et al. Chondrocalcinosis secondary to hypomagnesemia in Gitelman’s syndrome. J Rheumatol. 2005;32:1840–1842
  77. Gupta R, Hu V, Reynolds T, et al. Sclerochoroidal calcification associated with Gitelman syndrome and calcium pyrophosphate dihydrate deposition. J Clin Pathol. 2005;58:1334–1335
  78. Cruz DN, Shaer AJ, Bia MJ Yale Gitelman’s and Bartter’s Syndrome Collaborative Study. Gitelman’s syndrome revisited: An evaluation of symptoms and health-related quality of life. Kidney Int. 2001;59:710–717
  79. Simon DB, Nelson-Williams C, Bia MJ, et al. Gitelman’s variant of Bartter syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet. 1996;12:24–30
  80. Ryan MP. Diuretics and potassium/magnesium depletion. Am J Med. 1987;82(suppl 3A):38–47
  81. Peters M, Jeck N, Reinalter SS, et al. Clinical presentation of genetically defined patients with hypokalemic salt-losing nephropathies. Am J Med. 2002;112:183–190
  82. Knoers NVAM, Jong de JC, Meij IC, et al. Genetic renal disorders with hypomagnesemia and hypocalciuria. J Nephrol. 2003;16:293–296
  83. Coto E, Rodríguez J, Jeck N, et al. A new mutation (intron 9+1G>T) in the SLC12A3 gene is linked to Gitelman syndrome in Gypsies. Kidney Int. 2004;65:25–29
  84. Lin S-H, Chian J-C, Huang C-C, et al. Phenotype and genotype analysis in Chinese patients with Gitelman’s syndrome. J Clin Endocrinol Metab. 2005;90:2500–2507
  85. De Jong JC, van der Vliet WA, van der Heuvel LPWJ, et al. Functional expression of mutations in the human NaCl cotransport: Evidence for impaired routing mechanisms in Gitelman’s syndrome. J Am Soc Nephrol. 2002;13:1442–1448
  86. Nijenhuis T, Vallon V, van der Kemp AWCM, et al. Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest. 2005;115:1651–1658
  87. Quamme GA. Renal magnesium handling: New insights in understanding old problems. Kidney Int. 1997;52:1180–1195
  88. Ljunghall S, Backman U, Danielson BG, et al. Calcium and magnesium metabolism during long-term treatment with thiazides. Scand J Urol Nephrol. 1981;15:257–262
  89. Dai LJ, Friedman PA, Quamme GA. Cellular mechanisms of chlorothiazide and potassium depletion on Mg2+ in mouse distal convoluted cells. Kidney Int. 1997;51:1008–1017
  90. Rouffinac de C, Quamme G. Renal magnesium handling and its hormonal control. Physiol Rev. 1994;74:305–322
  91. Solomon R. The relationship between disorders of K and Mg homeostasis. Semin Nephrol. 1987;7:253–262
  92. Laine J, Jalanko H, Alakulppi , et al. A new tubular disorder with hypokalaemic metabolic alkalosis, severe hypomagnesaemia, hypercalciuria and cardiomyopathy. Nephrol Dial Trasplant. 2005;20:1241–1245
  93. Schepkens H, Hoeben H, Vanholder R, et al. Mimicry of surreptitious diuretic ingestion and the ability to make a genetic diagnosis. Clin Nephrol. 2001;55:233–237
  94. Ariceta G, Rodríguez Soriano J, Vallo A, et al. Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med Pediatr Oncol. 1997;28:35–40
  95. Barakat AJ, Rennert OM. Gitelman’s syndrome (familial hypokalemia-hypomagnesemia). J Nephrol. 2001;14:43–47
  96. Ariceta G, Rodríguez Soriano J. Magnesium. In:  Grimble GK,  Predddy VR,  Watson RR editor. Nutrition and the infant: Practice and procedures. Cambridge, UK: Greenwich Medical Media, Ltd; 2001;p. 149–158
  97. Dyckner T, Wester P, Widman L. Amiloride prevents thiazide-induced intracellular potassium and magnesium losses. Acta Med Scand. 1988;224:25
  98. Cortesi C, Foglia PEG, Bettinelli A, et al. Prevention of cardiac arrhythmias in pediatric patients with normotensive-hypokalemic tubulopathy. Pediatr Nephrol. 2003;18:729–730
  99. Bettinelli A, Tosetto C, Colussi G, et al. Electrocardiogram with prolonged QT interval in Gitelman disease. Kidney Int. 2002;62:580–584
  100. Yiu VWY, Dluhy R, Lifton RP, et al. Low peripheral plasma renin activity (PRA) as a critical marker in pediatric hypertension. Pediatr Nephrol. 1997;11:343–346
  101. Scheinman SJ, Guay-Woddford LM, Thakker RV, et al. Genetic disorders of renal electrolyte transport. N Engl J Med. 1999;15:1177–1187
  102. Liddle GW, Bledsoe T, Coppage WS. A familial renal disorder simulating primary hyperaldosteronism but with negligible aldosterone secretion. Trans Am Assoc Physicians. 1963;76:199–213
  103. Botero-Velez M, Curtis JJ, Warnock DG. Liddle’s syndrome revisited—a disorder of sodium reabsorption in the distal tubule. N Engl J Med. 1994;330:178–181
  104. Warnock DG. Liddle syndrome: Genetics and mechanisms of Na+ channel defects. Am J Med Sci. 2001;322:302–307
  105. Shimkets RA, Warnock DG, Bositis CM, et al. Liddle’s syndrome: Heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell. 1994;79:407–414
  106. Hansson JH, Nelson-Williams C, Suzuki H, et al. Hypertension caused by a truncated epithelial sodium channel gamma subunit: Genetic heterogeneity of Liddle’s syndrome. Nat Genet. 1995;11:76–82
  107. Vallon V, Lang F. New insights into the role of serum- and glucocorticoid-inducible kinase SGK1 in the regulation of renal function and blood pressure. Curr Opin Nephrol Hypertens. 2005;14:59–66
  108. Abriel H, Loffing J, Rebhun JF, et al. Defective regulation of the epithelial Na+ channel by Nedd4 in Liddle’s syndrome. J Clin Invest. 1999;103:667–673
  109. Snyder PM, Olson DR, McDonald FJ, et al. Multiple WW domains, but not the C2 domain, are required for inhibition of the epithelial Na+ channel by human Nedd4. J Biol Chem. 2001;276:28321–28326
  110. Kamynina E, Debonneville C, Bens M, et al. A novel mouse Nedd4 protein suppresses the activity of the epithelial Na+ channel. FASEB J. 2001;15:204–214
  111. Wong ZYH, Stebbing M, Ellis JA, et al. Genetic linkage of β and γ subunits of epithelial sodium channel to systolic blood pressure. Lancet. 1999;353:1222–1225
  112. Su YR, Rutkowski MP, Klanke CA, et al. A novel variant of the b-subunit of the amiloride-sensitive sodium channel in African Americans. J Am Soc Nephrol. 1996;7:2543–2549
  113. Smith PR, Benos DJ. Epithelial Na+ channels. Annu Rev Physiol. 1999;53:509–530
  114. New MI, Levine EG, Biglieri EG, et al. Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension. J Clin Endocrinol Metab. 1977;44:924–933
  115. Monder C, Shackleton CHL, Bradlow HL, et al. The syndrome of apparent mineralocorticoid excess: its association with 11-beta-dehydrogenase and 5-bet-reductase deficiency and some consequences for corticosteroid metabolism. J Clin Endocrinol Metab. 1986;63:550–557
  116. White PC, Mune T, Agarwal AK. 11 β-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev. 1997;18:135–156
  117. Wilson RC, Krozowski ZS, Li K, et al. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1995;80:2263–2266
  118. Wilson RC, Dave-Sharma S, Wei JQ, et al. A genetic defect resulting in mild low-renin hypertension. Proc Natl Acad Sci U S A. 1998;95:10200–10205
  119. Moudgil A, Rodich G, Jordan SC, et al. Nephrocalcinosis and renal cysts associated with apparent mineralocorticoid excess. Pediatr Nephrol. 2000;15:60–62
  120. Agarwal AK, Rogerson FM, Mune T, et al. Gene structure and chromosomal localization of the human HSD11K gene encoding the kidney (type 2) isozyme of 11-beta-hydroxysteroid dehydrogenase. Genomics. 1995;29:195–199
  121. Funder JW, Pearce PT, Smith R, et al. Mineralocorticoid action: Target tissue specificity is enzyme, not receptor, mediated. Science. 1988;242:583–585
  122. New MI. Hypertension in congenital adrenal hyperplasia and apparent mineralocorticoid excess. Ann N Y Acad Sci. 2002;970:145–154
  123. Dave-Sharma AS, Wilson RC, Harbison MD, et al. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1998;83:2244–2254
  124. Walker BR, Edwards CR. Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess. Endocrinol Metab Clin North Am. 1994;23:359–377
  125. Burgio E, Zammardi E, Vierucci A, et al. Un caso di pseudoiperaldosteronismo da ingestione di liquirizia. Riv Ital Pediatr. 1980;6:391–392
  126. Palermo M, Delitala G, Sorba G, et al. Does kidney transplantation normalize cortisol metabolism in apparent mineralocorticoid excess syndrome?. J Endocrinol Invest. 2000;23:457–462
  127. Geller DS, Farhi A, Pinkerton N, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science. 2000;289:119–123
  128. Stowasser M, Gordon RD. Familial hyperaldosteronism. J Steroid Biochem Mol Biol. 2001;78:215–229
  129. McMahon GT, Dluby R. Glucocorticoid-remediable aldosteronism. Cardiol Rev. 2004;12:44–48
  130. Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. CMAJ. 1966;95:1109–1119
  131. Gordon RD. Heterogeneous hypertension. Nat Genet. 1995;11:6–9
  132. Lifton RP, Dluhy RG, Powers M, et al. A chimeric 11-beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355:262–265
  133. Lifton RP, Dluhy RG, Powers M, et al. Hereditary hypertension caused by chimeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet. 1992;2:6–74
  134. Litchfield WR, New MI, Coolidge C, et al. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab. 1997;82:3570–3573
  135. Dluhy RG, Anderson B, Harlin B, et al. Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood. J Pediatr. 2001;138:715–720
  136. Kater CE, Biglieri EG. The syndromes of low-renin hypertension: “Separating the wheat from the chaff.”. Arq Bras Endocrinol Metabol. 2004;48:674–681

PII: S0270-9295(06)00142-2

doi: 10.1016/j.semnephrol.2006.10.002

Seminars in Nephrology
Volume 26, Issue 6 , Pages 422-433 , November 2006

Article Tools

* Image Usage & Resolution